Pricing Log in Create free account

Mineralys Therapeutics, Inc. (MLYS) vs Xencor, Inc. (XNCR)

Mineralys Therapeutics, Inc. and Xencor, Inc. are both Biotechnology companies. Mineralys Therapeutics, Inc. and Xencor, Inc. are of similar size ($1.9B and $1.9B). Mineralys Therapeutics, Inc. has the higher net margin (0.00% vs −155.6%) and the higher return on invested capital (0.00% vs −288.7%). Across the 13 metrics below, Mineralys Therapeutics, Inc. leads on 7 and Xencor, Inc. on 6.

Valuation

Metric MLYS XNCR Biotechnology median
P/E n/m n/m 8.58
P/S n/m 18.72 10.29
P/B 3.28 3.90 2.29
Price to free cash flow n/m n/m 21.93
EV/EBITDA n/m n/m 0.67
EV/Sales n/m 15.51 9.89
Earnings yield (19.86%) (8.38%) (31.56%)
Free cash flow yield (7.68%) (10.65%) (23.42%)

Profitability

Metric MLYS XNCR Biotechnology median
Gross margin — 100.00% 65.77%
Operating margin 0.00% (205.84%) 0.00%
Net margin 0.00% (155.59%) 0.00%
Free cash flow margin 0.00% (198.42%) 0.00%
Return on equity (80.88%) (29.07%) (54.09%)
Return on assets (69.67%) (20.36%) (47.78%)
Return on invested capital 0.00% (288.71%) 0.00%

Growth

Metric MLYS XNCR Biotechnology median
Revenue growth (TTM) — (28.56%) 5.83%
EPS growth (last fiscal year) 37.43% 65.36% 29.36%
Revenue growth, 5-year CAGR — 0.47% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric MLYS XNCR Biotechnology median
Debt to equity 0.18 0.00 0.00
Current ratio 34.46 6.39 4.80
Net debt to EBITDA 3.85 2.51 0.97

Dividend

Metric MLYS XNCR Biotechnology median
Dividend yield — — 0.44%
Payout ratio — — —

Size

Metric MLYS XNCR Biotechnology median
Market cap 1.87b 1.87b 153.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack